ReviewFrontiers in immunology2025
Chemokines and their receptors in oral squamous cell carcinoma: mechanisms, clinical significance, and therapeutic implications.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemokines, a category of cytokines exhibiting chemotactic properties, have been thoroughly investigated as targets in cancer treatment in recent decades. In oral squamous cell carcinoma (OSCC), a prevalent and high-risk malignancy of the head and neck, chemokines interact with their specific receptors to initiate downstream signaling pathways. This signaling influences not only tumor cell proliferation, migration, invasion, and metastasis of oral cancer cells but also angiogenesis and vascular maturation. Furthermore, they modulate the tumor microenvironment (TME), which consists of diverse cellular and molecular components that collectively create a permissive niche for tumor growth, metastasis, and therapeutic resistance. This modulation impacts the recruitment and functionality of immune cells, which in turn influences tumor immune evasion and immune surveillance. Various chemokines and their receptors have distinct expression patterns in oral cancer tissues compared to normal tissues. Certain chemokines may function as prospective diagnostic markers, prognostic indicators, and therapeutic targets. In this review, we systematically summarize research advancements on chemokines in OSCC, elucidating their molecular mechanisms in tumor initiation and progression with a focus on the dualistic roles of key chemokine families (e.g., CCL2/5/20/19/21, CXCL1/8/12, CX3CL1) in regulating immune responses, tumor-stroma interactions, vascular remodeling, and chemotherapy resistance. We also recap current chemokine/receptor-targeted therapeutic strategies and discuss the limitations of existing research, including incomplete mechanistic understanding of understudied chemokine subfamilies (beyond CXC and CC subfamilies) and limited clinical translation of chemokine-based diagnostics and therapeutics. Finally, we propose future research directions: prioritizing patient stratification based on chemokine profiles, developing targeted delivery systems for chemokine antagonists, and combining these approaches with emerging therapies to overcome treatment resistance. This review underscores the critical role of chemokines in OSCC biology and their promising potential to guide the development of novel, effective therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.